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Coating of a Novel Antimicrobial Nanoparticle with 
a Macrophage Membrane for the Selective Entry into 
Infected Macrophages and Killing of Intracellular 
Staphylococci
Yuanfeng Li, Yong Liu, Yijin Ren, Linzhu Su, Ang Li, Yingli An, Vincent Rotello, 
Zhanzhan Zhang, Yin Wang, Yang Liu, Sidi Liu, Jian Liu, Jon D. Laman, Linqi Shi,* 
Henny C. van der Mei,* and Henk J. Busscher
Internalization of Staphylococcus aureus by macrophages can inactivate bacte-
rial killing mechanisms, allowing intracellular residence and dissemination of 
infection. Concurrently, these staphylococci can evade antibiotics that are fre-
quently unable to pass mammalian cell membranes. A binary, amphiphilic con-
jugate composed of triclosan and ciprofloxacin is synthesized that self-assemble 
through micelle formation into antimicrobial nanoparticles (ANPs). These 
novel ANPs are stabilized through encapsulation in macrophage membranes, 
providing membrane-encapsulated, antimicrobial-conjugated NPs (Me-ANPs) 
with similar protein activity, Toll-like receptor expression and negative surface 
charge as their precursor murine macrophage/human monocyte cell lines. The 
combination of Toll-like receptors and negative surface charge allows uptake 
of Me-ANPs by infected macrophages/monocytes through positively charged, 
lysozyme-rich membrane scars created during staphylococcal engulfment. 
Me-ANPs are not engulfed by more negatively charged sterile cells possessing 
less lysozyme at their surface. The Me-ANPs kill staphylococci internalized in 
macrophages in vitro. Me-ANPs likewise kill staphylococci more effectively 
than ANPs without membrane-encapsulation or clinically used ciprofloxacin in 
a mouse peritoneal infection model. Similarly, organ infections in mice created 
by dissemination of infected macrophages through circulation in the blood are 
better eradicated by Me-ANPs than by ciprofloxacin. These unique antimicrobial 
properties of macrophage-monocyte Me-ANPs provide a promising direction for 
human clinical application to combat persistent infections.
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1. Introduction
Infection by antimicrobial resistant bac-
teria is predicted to yield more deaths 
than cancer, and become the number one 
cause of death by 2050, due in a large 
part to the growing number of antibiotic-
resistant strains.[1] The challenges gen-
erated by this emerging resistance are 
exacerbated by native mechanisms used 
by bacteria to evade antimicrobials. One 
way infectious bacteria evade antibiotic 
action and killing by host immune cells 
is by “hiding” in mammalian cells, a 
pathway that can increase the severity of 
disease and hampers pathogen eradica-
tion.[2,3] The mammalian cell membrane 
acts as a barrier toward penetration of 
many antibiotics,[4] which makes the intra-
cellular environment a protective shelter 
for infecting bacteria. Moreover, the diver-
sity spectrum of enzymes present in host 
mammalian cells can inactivate antibiotics 
to further protect bacteria hiding intracel-
lularly. Even macrophages, intended by 
nature to facilitate bacterial clearance from 
the body, can provide intracellular shelter 
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to infecting bacteria.[5] In fact, many intracellular bacterial 
pathogens replicate in the shelter provided by macrophages.[6] 
After engulfment, bacteria initially reside in membrane-bound 
phagosomes,[7] that fuse with lysosomes to form phagolys-
osomes in which bacteria are normally killed by reactive oxygen 
species, lysozyme and cationic antimicrobial peptides. However, 
bacteria can remain dormant in the low pH environment of 
phagosomes as well as reside in phagolysosomes for extended 
periods of time.[8–11] Moreover, intracellular Staphylococcus 
aureus can delay phagosome fusion with lysozyme for at least 
28 h,[12] allowing staphylococci to survive and develop resistance 
to reactive oxygen species and antimicrobial peptides.[7,13] Apart 
from bacterial survival, these combined mechanisms allow 
dissemination of infection through the body by circulation of 
infected macrophages in the blood.[14] Effective evasion strate-
gies based on hiding in macrophages have been developed by 
multiple pathogenic bacterial strains, such as Mycobacterium 
tuberculosis, S. aureus and Salmonella enterica.[15] Frequently, 
extremely high doses of antibiotics are needed to kill intracel-
lular bacteria and prevent their dissemination through circula-
tion in the blood. High dosing can lead to severe side effects for 
the patients, while being still insufficient to cure infection.[16,17] 
Overall, eradication of bacteria hiding in macrophages is cru-
cial for the long-term success of antibiotic treatment.[18,19]
With the number of antibiotics available to eradicate bacte-
rial infections shrinking at an alarming rate,[20–22] new strate-
gies to eradicate bacteria hiding intracellularly in macrophages 
and prevent dissemination of infection through the body, are 
direly needed. Azithromycin and ciprofloxacin can be effec-
tively delivered intracellularly in high amounts when encapsu-
lated in either negatively- or positively charged liposomes.[23] 
Equipping liposomes with a cell penetrating protein enhanced 
intracellular delivery of gentamicin,[15] while colistin-loaded 
liposomes equipped with extracellular adherence proteins 
from S. aureus facilitated entry into HEp-2 and Caco-2 cells and 
killed intracellular S. enterica.[24] These liposomes enter mam-
malian cells through membrane fusion, but their fusogenicity 
comes at the expense of their stability,[25] and liposomes 
with increased fusogenicity are more prone to rupture and 
inadvertent cargo release.[26,27] Synthetic antimicrobial nanopar-
ticles (ANP) can be made more stable by a variety of strategies, 
but are easily cleared by host immune cells.[28] To avoid clear-
ance by host immune cells and facilitate their transportation 
through the blood circulation, synthetic antimicrobial nanocar-
riers can be equipped with stealth properties and pH respon-
siveness that make them suitable for use in infection control.[29] 
In general however, synthetic nanocarriers are hard to render 
biocompatible.
Cell membrane surfaces, by nature meet many of the bio-
compatibility requirements that are challenging in the design of 
synthetic nanocarriers.[30] Red blood cell, leukocyte, cancer cell, 
and platelet membrane-coated nanoparticles have been dubbed 
as “autogenous friends” with incredibly long blood circulation 
times to assist tumor therapy.[31] Cell membrane-coated nanopar-
ticles are known for their immune modulating properties and 
their potential for detoxification.[32] Biomimetic red-blood cell 
membrane-encapsulated nanoparticles, for instance, have been 
applied for detoxification of organophosphate poisoning,[33,34] 
while leukocyte membrane-encapsulated NPs can absorb endo-
toxins during sepsis treatment.[35] Encapsulation by leukocyte 
membranes of NPs also inhibited synovial inflammation and 
alleviated joint damage.[36] Bacterially stimulated macrophage 
membrane-coated gold–silver nanocages targeted themselves 
to bacterial cell surfaces in an extracellular environment.[37] The 
use of bacterially pretreated macrophage membranes for encap-
sulation of nanoparticles (NPs) is highly unpractical however, 
and to our knowledge native macrophage membrane-encapsu-
lated NPs have not yet been applied to cure intracellular bacte-
rial infections that are even more difficult to treat than extracel-
lular infections and form a cause of recurrence. Thus, inspired 
by the natural biocompatibility of unstimulated macrophages, 
we encapsulated ANPs in membranes from J774A.1 (as a model 
for mouse macrophages) and THP-1 (as a model for human 
monocytes) to provide membrane-encapsulated, antimicrobial 
NPs (Me-ANPs) that take advantage of the biocompatibility, 
resistance to clearance by host immune cells, and bacterial path-
ogen-targeting ability that macrophages possess by nature.[30]
The novel ANPs that provide the foundation of our system 
were composed of amphiphilic, binary antimicrobial-conjugates 
composed of a hydrophobic antimicrobial, triclosan, and a 
common clinically applied, more hydrophilic antibiotic, cipro-
floxacin (Figure  1). Triclosan was chosen as an antimicrobial, 
because it is not only a common oral antimicrobial in tooth-
pastes and mouthwashes,[38] but also applied in antimicrobial 
sutures[39] and other clinical infection control measures.[40] The 
amphiphilic antimicrobial-conjugates self-assembled into ANPs 
that were subsequently stabilized by macrophage-monocyte 
membrane-encapsulation. The killing efficacy of Me-ANPs 
toward bacteria hiding in macrophages was demonstrated both 
in vitro and in vivo, using S. aureus as an infecting organism. 
S. aureus is a leading cause of severe bacterial infections world-
wide and currently regarded as one of the most prevalent 
 intracellular human pathogen.[41] S. aureus is hard to kill once 
intracellularly present.[42,43] Both in a mouse peritoneal infection 
model as well as in a mouse organ infection model, infection was 
more effectively eradicated by macrophage membrane-encapsu-
lated Me-ANPs than by ANPs without membrane-encapsulation 
or ciprofloxacin, a common antibiotic in clinical practice.
2. Results
2.1. Preparation and Characterization of Macrophage-Monocyte 
Membrane-Encapsulated, Antimicrobial-Conjugated Nanoparticles
Amphiphilic, binary antimicrobial-conjugates were synthe-
sized via chloroacetylation of triclosan and subsequent chloride 
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substitution using ciprofloxacin with an overall yield of 70%. 
The antimicrobial-conjugate composition was confirmed by 
1H and 13C NMR (Figures S1 and S2, respectively, Supporting 
information) and electrospray ionization mass spectrometry 
(Figure S3, Supporting Information). Conjugation was done 
through reacting the hydroxyl group of triclosan and the sec-
ondary amine group of ciprofloxacin. These groups were 
selected because esterification of the phenol group of triclosan 
and alkylation of the piperazinyl group of ciprofloxacin have 
been demonstrated to have little negative effect on antimicrobial 
efficacy.[44,45] The critical micelle concentration of the antimi-
crobial conjugate was 0.38 µg mL−1 (Figure S4, Supporting 
Information). For self-assembly of the amphiphilic antimicro-
bial-conjugate through micelle formation into an antimicrobial 
NP-template, conjugates were dissolved in dimethylsulfoxide, 
added dropwise into water and centrifuged to remove the 
organic solvent.[46] Next, membranes isolated from mouse 
J774A.1 cells were mixed with the NPs to obtain J774A.1 Me-
ANPs. Electron microscopy showed spherically-shaped ANPs 
and Me-ANPs after 24 h in a 10 × 10−3 m potassium phosphate 
buffer at pH 7.4, with the encapsulating membrane clearly vis-
ible (Figure 2a). Me-ANPs partly disassembled after 24 h expo-
sure to pH 5.0, but not at the physiological pH of 7.4 (Figure 2a). 
Freshly made ANPs had diameters of around 90 nm (Figure 2b) 
with a polydispersity index (PDI) of 0.11 in absence of J774A.1 
membrane-encapsulation. After 2 weeks storage in potassium 
phosphate buffer at pH 7.4, ANP diameters increased roughly 
twofold, indicative of the water uptake. Membrane-encapsulation 
Figure 1. Design, synthesis and hypothesized mechanism of macrophage-monocyte membrane-encapsulated, antimicrobial-conjugated nanoparticles 
(Me-ANPs) to kill intracellular bacterial pathogens, hiding inside leukocytes. a) Preparation of a hydrophobic antimicrobial (triclosan) and a more 
hydrophilic antibiotic (ciprofloxacin) into an amphiphilic, binary antimicrobial-conjugate that self-assembles through micelle formation in aqueous 
solution to form antimicrobial NPs. b) Isolation of leukocyte membranes. c) Stabilization of self-assembled, antimicrobial NPs by encapsulation in leu-
kocyte membranes. d) Macrophage-monocytes Me-ANPs are naturally engulfed into an infected macrophage. e) Once inside an infected macrophage, 
intracellular release of conjugated antimicrobials from Me-ANPs kills infecting bacteria. Details not drawn to scale.
Adv. Funct. Mater. 2020, 2004942
www.afm-journal.dewww.advancedsciencenews.com
2004942 (4 of 16) © 2020 The Authors. Published by Wiley-VCH GmbH
yielded an increase in diameter to around 110 nm and in PDI to 
0.13. Moreover, membrane encapsulation stabilized the Me-ANP 
diameter up to at least 4 weeks after preparation. Liquid chro-
matography-mass spectrometry (LC-MS) analysis[28,47] indi-
cated that 79% of the proteins found on J774A.1 Me-ANPs were 
membrane proteins (Figure 2c), as confirmed by the similarity 
in molecular mass distributions in J774A.1 membranes and 
Me-ANPs (Figure  2d). Toll-like receptors involved in recogni-
tion of bacterial lipopolysaccharides and lipoteichoic acids, i.e., 
cell membrane derived TLR2 and TLR4 as well as endosomal 
Figure 2. Characteristics of mouse J774A.1 membrane-encapsulated, antimicrobial-conjugated nanoparticles (Me-ANPs). a) Transmission electron 
micrographs of a negative-stained (0.5% uranyl acetate) ANP and a Me-ANP after 24 h in 10 × 10−3 M potassium phosphate buffer at different pH, 
showing membrane-encapsulation as a dark area around the NP. Note partial disassembly of the Me-ANP at pH 5.0. Lower magnification electron 
micrographs showing more ANPs are presented in Figure S5 (Supporting Information). b) Hydrodynamic diameters in 10 × 10−3 M potassium phos-
phate buffer of ANPs in absence and presence of membrane-encapsulation, as a function of storage time in buffer. Data were expressed as means ± 
standard deviations over triplicate nanocarrier preparations. c) The number of J774A.1 membrane proteins and other proteins on Me-ANP identified by 
liquid chromatography-mass spectrometry (LC-MS). d) Molecular mass (kDA) distribution of membrane proteins in mouse J774A.1 membranes and 
Me-ANPs by LC-MS. e) Relative abundance of Toll-like receptors identified using LC-MS involved in bacterial recognition on J774A.1 membranes and 
Me-ANPs. and abundance of TLR-2 in J774A.1 membranes set at 100%. f) Functional characterization of membrane proteins identified on Me-ANPs. 
Proteins were classified according to UniProt/GO database[51] using the LC-MS data as input. g) Same as panel (d), now for the distribution of iso-
electric points of membrane proteins. h) Zeta potentials in 10 × 10−3 M potassium phosphate buffer of ANPs in absence and presence of membrane-
encapsulation, as a function of storage time in buffer. Data were expressed as means ± standard deviations over triplicate nanocarrier preparations. 
i) Antimicrobial-conjugate content in wt% of Me-ANPs, expressed relative to the initial antimicrobial-conjugate content of ANPs in absence of encap-
sulation. Antimicrobial-conjugate contents were derived from UV–vis spectroscopy (see Figure S6, Supporting Information). Data are expressed 
as means ± standard deviations over triplicate nanocarrier preparations. Asterisks above the data points indicate statistical significance at p < 0.05 
(*, Student’s t-test) between ANPs and Me-ANPs.
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membrane-derived TLR3 and TLR9,[48–50] were also abundantly 
present both on J774A.1 membranes and Me-ANPs (Figure 2e). 
A functional classification based on UniProt/GO[51] analysis 
using the LC-MS data as input, identified the membrane pro-
teins on Me-ANPs to be involved in transport (40%), signaling 
(32%), immunity (12%) and metabolism (7%) (Figure 2f). This 
functional classification is in line with protein functions in 
J774A.1 membranes.[52] Actual protein activity is virtually impos-
sible to measure in a mixture of over 4000 proteins identified 
in a macrophage membrane, but absence of denaturation can 
be anticipated based on absence of aggregation and precipita-
tion (common to denatured proteins) of Me-ANPs over a period 
of four weeks. This makes maintenance of functional protein 
activity likely. Based on isoelectric points (pI; Figure  2g), the 
percentages of positively (pI > 7) and negatively (pI < 7) charged 
proteins were equal for J774A.1 membranes and Me-ANPs. Few 
(<9%) highly negatively charged proteins (pI <  5) were identi-
fied, while more than 20% of the proteins carried a high positive 
charge (pI >  9). Accordingly, J774A.1 membrane-encapsulation 
compensated the highly negative zeta potential of ANPs in 
absence of a membrane coating, yielding stable, negative zeta 
potentials of around −25 mV over the course of at least 4 weeks 
(Figure  2h). Using UV–vis absorption spectroscopy and set-
ting the antimicrobial-conjugate content of ANPs in absence of 
encapsulation at 100% (see Figure S6, Supporting Information), 
additional antimicrobial-conjugates were found to be captured 
during the encapsulation process (Figure 2i). Thus, membrane-
encapsulation of ANPs not only stabilized the particles, but also 
increased their antimicrobial-conjugate content.
Exposure of J774A.1 Me-ANPs to phosphate buffered saline 
(PBS) at pH 7.4 only yielded partial release of <50 wt% of the 
antimicrobial-conjugates over 72 h (Figure  3), but at a lower 
pH, as prevalent in macrophage sub-cellular compartments,[53] 
nearly 100% of the antimicrobial-conjugates was released. This 
enhanced release at low pH, particularly increasing after 24 h, 
is due to the pH dependent disassembly of Me-ANPs, occur-
ring only in a low pH environment (see also Figure 2a), which 
is an advantageous feature yielding enhanced availability of 
the antimicrobials in the same sub-cellular compartments as 
in which also bacteria reside. Note from Figures 2a and 3, that 
this disassembly is a slow process occurring over a time scale 
of around 24 h. Disassembly of Me-ANPs in a low pH environ-
ment (pH 5.0) likely arises through protonation of three tertiary 
amine groups on the antimicrobial conjugate (see Figure  1), 
possessing pKa’s around 4.85 (ChemDraw calculation). Proto-
nation of the amine groups increases the hydrophilicity of the 
conjugate, which disrupts the balance between its hydrophobic 
and hydrophilic part that provides the basis for macrophage 
membrane-stabilized ANP formation.
In a separate series of experiments, Figure S7a–h (Sup-
porting Information) show that encapsulation of ANPs by 
human THP-1 cells, modeling monocytes, yielded similar 
stabilization of the nanoparticle diameters and other impor-
tant properties, including antimicrobial-conjugate release and 
membrane protein function in the coating as encapsulation by 
mouse J774A.1 cells.
2.2. Engulfment of Macrophage-Monocyte Membrane-
Encapsulated, Antimicrobial-Conjugated Nanoparticles 
into Macrophages In Vitro
To demonstrate engulfment of J774A.1 Me-ANPs into sterile 
and infected J774A.1 cells, Me-ANPs were loaded with hydro-
phobic fluorescent Nile red. To obtain infected J774A.1 cells with 
in vitro internalized S. aureus, overnight cultures of staphylo-
cocci and cells were grown to internalize staphylococci inside 
the macrophages, while washing off extracellular bacteria 
and killing possible remaining extra-cellular staphylococci by 
exposure to gentamicin.[16,54,55] Intracellular presence of staph-
ylococci was clearly indicated in CLSM images of green-fluores-
cent staphylococci inside J774A.1 macrophages (see Figure 4a).
Next, J774A.1 macrophages with or without intracellular 
green-fluorescent S. aureus WHGFP were exposed to suspen-
sions of Nile red-loaded, Me-ANPs in PBS and imaged using 
CLSM. Surprisingly, Me-ANPs can be seen to be exclusively 
engulfed by infected mouse J774A.1 macrophages with intra-
cellular staphylococci, but not microscopically visible by 
sterile J774A.1 cells (see also Figure  4a). Similarly, no engulf-
ment was observed of Nile red-loaded ANPs encapsulated in 
negatively-charged (zeta potential −10  mV)[56] phosphocholine 
liposomes,[52] both for J774A.1 cells without and with intra-
cellular staphylococci. The above conclusions drawn from 
Figure  4a were supported by quantitative analyses of the red-
fluorescence intensity per macrophage averaged over multiple 
nanocarrier preparations and macrophages as presented in 
Figure  4b. However, a very small fluorescence intensity was 
measured for sterile J774A.1 cells compared to infected mac-
rophages, indicating minor engulfment of Me-ANPs by sterile 
J774A.1. Me-ANPs encapsulated by THP-1 cells as a model cell 
line for human monocytes, yielded the same, selective engulf-
ment into infected J774A.1 cells, as exhibited by mouse J774A.1 
Me-ANPs (Figure S7i, Supporting Information).
Figure 3. Cumulative antimicrobial-conjugate release from mouse J774A.1 
membrane-encapsulated antimicrobial-conjugated nanoparticles as a 
function of exposure time to phosphate buffered saline (PBS: 10 × 10−3 m 
potassium phosphate with 150 × 10−3 m NaCl added) at pH 5.0 and 7.4. 
The discontinuity in the release curve at pH 5.0 at around 24 h is likely 
related to disassembly of the nanoparticles (compare Figure 2a). Drug 
release was measured using UV–vis spectroscopy. Data are expressed 
as means ± standard deviations over triplicate nanocarrier preparations.
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2.3. Selectivity of Me-ANPs towards Infected versus Sterile 
Macrophages
In order to find differences between sterile and infected macro-
phages relevant for the selectivity of membrane-encapsulated 
ANPs towards infected macrophages, we compared the zeta 
potentials of J774A.1 membrane fragments from sterile and 
infected cells in 10 × 10−3 m potassium phosphate buffer.
Membrane fragments from sterile cells had a significantly 
more negative zeta potential (-47 ± 3 mV), than Me-ANPs (see 
Figure 2h). Membrane fragments of infected cells, were 10 mV 
less negatively-charged (zeta potential -37 ± 3  mV) than when 
isolated from sterile cells. The less negative zeta potentials of 
cell membranes after staphylococcal infection, suggests capture 
of positively charged antimicrobial proteins in the membrane 
during staphylococcal engulfment. For this, lysozyme is a clear 
candidate protein, as it is a positively charged antimicrobial 
used by leukocytes for intra- and extraleukocyte degradation 
of bacterial cell wall peptidoglycans, hydrolyzation the glycan 
backbone, and killing bacteria through its cationic features.[57,58] 
Fluorescence labeling with anti-lysozyme antibodies of infected 
mouse J774A.1 cells demonstrated small lysozyme-rich spots, 
coinciding with the likely (see also Figure S9, Supporting Infor-
mation) point of staphylococcal engulfment, that were absent on 
sterile cells (Figure 5a). Quantification of red-fluorescence inten-
sity of lysozyme in CLSM images was found significantly higher 
(p < 0.001, Student’s t-test) in infected J774A.1 cells than in sterile 
ones (Figure 5b), in line with the less negative zeta potential of 
infected J774A.1 cells. These positively-charged, lysozyme scars 
present the likely point of entry of negatively-charged Me-ANPs 
as a result of the electrostatic double-layer interaction between 
opposite charges. Human THP-1 cells immediately after infec-
tion demonstrated similar lysozyme scars and overall higher 
lysozyme presence as observed for infected mouse J774A.1 cells 
(compare Figure  5 and Figure S11, Supporting Information). 
Considering the possibility that lysozyme concentrated in the 
scar-region diffuses to equally distribute over the cell membrane, 
lysozyme scars on J774A.1 cells were monitored as a function of 
time after infection. Lysozymes scars remained present over at 
least 12 h after infection in CLSM images (see also Figure 5a). 
This result is supported by flow cytometry (Figure 5c), indicating 
that the lysozyme levels on infected cells were significantly 
above the lysozyme levels on sterile cells at all points in time up 
to minimally 12 h (Figure 5d). Thus, the window of opportunity 
for selective entry of Me-ANPs into infected macrophages is at 
minimum 12 h.
2.4. Antimicrobial Efficacy of Macrophage-Monocyte Membrane-
Encapsulated, Antimicrobial-Conjugated Nanoparticles In Vitro
First, to establish whether antimicrobial conjugation and leu-
kocyte membrane-encapsulation had affected the antimicrobial 
efficacy of the composing antimicrobials, their minimal inhibi-
tory and bactericidal concentrations (MIC and MBC, respec-
tively) towards two multidrug resistant[22] S. aureus strains were 
compared with those of triclosan or ciprofloxacin in solution 
or a solution with equal concentrations of both antimicrobials. 
Figure 4. Engulfment of mouse J774A.1 membrane-encapsulated, antimicrobial-conjugated nanoparticles by infected and sterile J774A.1 macrophages 
with and without in vitro internalized green-fluorescent S. aureus WHGFP, respectively (2 h exposure time). Experiments were done in PBS. ANPs 
encapsulated in phosphocholine liposomes (PC-liposomes) are included as a negative control. a) CLSM images illustrating intracellular presence 
of green-fluorescent staphylococci (arrows) with attached Nile red-loaded, membrane or liposome encapsulated ANPs into J774A.1 macrophages 
with or without intracellular S. aureus. J774A.1 nuclei were blue-fluorescently stained using DAPI. Lower magnification CLSM images showing more 
macrophages are presented in Figure S8 (Supporting Information). b) Red-fluorescence intensity of Nile red-loaded, membrane or liposome encap-
sulated ANPs after engulfment in J774A.1 macrophages with or without intracellular S. aureus. Data were expressed as a mean fluorescence intensity 
per macrophage ± standard deviations over triplicate nanocarrier preparations. Three images were blindly chosen in each experiment, comprising on 
average ≈15 macrophages per image.
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MICs and MBCs of a solution with equal concentrations of 
triclosan and ciprofloxacin were one serial dilution lower for 
MIC than of solutions with only triclosan or ciprofloxacin, 
which is a microbiologically negligible difference. MBC values 
were likewise similar (Figure 6a). J774A.1 Me-ANPs had twofold 
lower MIC and fourfold lower MBC than corresponding solu-
tions of both antimicrobials. Thus, it can be conservatively con-
cluded, that neither conjugation nor membrane-encapsulation 
negatively affected antimicrobial efficacy, pointing to a cor-
rect choice of the triclosan and ciprofloxacin sites sacrificed 
Figure 5. Lysozyme presence on sterile and infected J774A.1 cells. Red-fluorescent anti-lysozyme antibodies were applied for labeling in absence of 
Triton X-100, labeling only lysozyme on the cell membrane.[59] a) Demonstration of red-fluorescent, lysozyme-rich scars in mouse J774A.1 cells after infec-
tion with green-fluorescent S. aureus WHGFP, including absence of lysozyme-rich scars on sterile cells using CLSM. Blue-fluorescence is due to DAPI 
staining of macrophage nuclei. Arrows point to a lysozyme-rich spot, coinciding with the likely engulfment-point of staphylococci in an infected cell. 
Lower magnification CLSM images are presented in Figure S10 (Supporting Information). b) Red-fluorescence intensity due to lysozyme on sterile and 
infected J774A.1 cells immediately after infection, measured from the intensity in CLSM images. Data were expressed as a mean fluorescence intensity 
per macrophage ± standard deviations over triplicate nanocarrier preparations. Three images were blindly chosen in each experiment, comprising on 
average ≈5 macrophages per image. Asterisks above the data points indicate statistical significance at p < 0.001 (***). c) Red-fluorescence counts on 
sterile J774A.1 and infected J774A.1 cells immediately (0 h) and 12 h after infection, measured using flow cytometry. d) Red-fluorescence intensity of 
lysozyme on sterile J774A.1 cells and infected J774A.1 cells as a function of time after infection. Data were expressed as a mean fluorescence intensity 
per macrophage ± standard deviations over triplicate nanocarrier preparations. Three images were blindly chosen in each experiment, comprising 
on average approximately 5 macrophages per image. Asterisks above the data points indicate statistical significance at p < 0.001 (***), p < 0.01 (**), 
Student’s t-test between sterile and infected cells at each time point.
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for conjugation. Human THP-1 monocyte membrane-encap-
sulation yielded identical MIC and MBC for both strains, as 
did mouse J774A.1 macrophage-membrane encapsulation 
(Figure S7j, Supporting Information).
Next, J774A.1 macrophages with in vitro internalized staphy-
lococci were exposed to different concentrations of either of the 
two antimicrobials, or J774A.1 Me-ANPs, while using PBS (pH 
7.4) as a negative control. Me-ANPs demonstrated two to three 
log-units better killing of intracellular staphylococci than tri-
closan, ciprofloxacin, or PBS (Figure 6b,c), both for internalized 
S. aureus WHGFP (Figure 6b) and internalized S. aureus Xen36 
(Figure 6c). Importantly, Figure 6b,c indicate that triclosan and 
ciprofloxacin killed fewer intracellular staphylococci than ANPs 
in the absence of J774A.1 membrane encapsulation, while ANPs 
without membrane-encapsulation killed bacteria less effectively 
than of membrane-encapsulated ones. Hence, the effects of 
the ANPs themselves and their membrane-encapsulation can 
be delineated, showing clearly the importance of both self-
assembly of the antimicrobial-conjugates into an antimicrobial 
nanoparticle and their membrane encapsulation (see Figure 1).
2.5. In Vitro Cytotoxicity of Macrophage-Monocyte Membrane-
Encapsulated, Antimicrobial-Conjugated Nanoparticles
Absence of cytotoxicity of Me-ANPs in vitro was demonstrated 
based on a metabolic activity assay applied for a variety of cell 
lines, including human skin fibroblasts, human epithelial colo-
rectal adenocarcinoma cells, murine macrophages and human 
monocytes (Figure S12, Supporting Information). Metabolic 
activity of neither cell line was negatively affected by growth in 
presence of Me-ANPs.
2.6. In Vivo Internalization of Staphylococci in Mouse 
Macrophages
A peritoneal infection model[60] provides a relatively easy tool 
(see schematics in Figure S13a, Supporting Information) to iso-
late peritoneal macrophages with in vivo internalized, intracel-
lular staphylococci.[61] To this end, staphylococci were injected 
in the peritoneal cavity of eight week-old female ICR (CD-1) 
mice. To obtain infected macrophages with in vivo internalized 
staphylococci, peritoneal fluid extract was taken 1 d after staphy-
lococcal injection, harvesting 5×107 macrophages mL−1 with on 
average 8 internalized staphylococci per cell (Figure S13b,c, 
Supporting Information).
2.7. Eradication of Peritoneal Infection in Mice Using Mac-
rophage Membrane-Encapsulated, Antimicrobial-Conjugated 
Nanoparticles
Acute peritoneal infection is a life-threatening condition 
invoking rapid action of macrophages to clear the infection.[61,62] 
Therefore, we first compared eradication of an acute perito-
nitis in mice by ciprofloxacin versus ANPs with (Me-ANPs) 
and without J774A.1 membrane-encapsulation, using PBS as a 
Figure 6. In vitro antimicrobial efficacy of mouse J774A.1 membrane-encapsulated, antimicrobial-conjugated nanoparticles (Me-ANPs), as compared 
with the composing antimicrobials in solution. a) Minimal inhibitory and bactericidal concentrations (MIC and MBC, respectively) in µg mL−1 of 
planktonic S. aureus WHGFP and S. aureus Xen36 in suspension for triclosan, ciprofloxacin, their combination, and ANPs without and with J774A.1 
membrane-encapsulation in PBS at pH 7.4. Experiments were done at equal concentrations of triclosan and ciprofloxacin. b) Colony forming units of 
surviving S. aureus WHGFP inside J774A.1 cells with in vitro internalized staphylococci after 24 h exposure to triclosan, ciprofloxacin in solution or ANPs 
with or without J774A.1 membrane-encapsulation. Data were represented by means ± standard deviations over triplicate experiments with independent 
bacterial cultures. The grey band indicates the initial numbers of CFU mL−1 in PBS. c) Same as panel (b), now for S. aureus Xen36.
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negative control (Figure 7a). Plating of homogenized intraperi-
toneal fluid extract (Figure  7b) yielded the highest CFU count 
after injection of PBS. Injection with ciprofloxacin yielded 
2 log-units fewer CFUs than PBS injection, while injection 
with APNs was a further 1 log-unit more effective in clearing 
staphylococci from peritoneal fluid than ciprofloxacin. How-
ever, treatment by Me-ANPs was most effective in eradicating 
acute peritonitis, reducing the number of peritoneal CFUs with 
respect to PBS by 4 log-units, which is significantly more than 
achieved by ANPs without J774A.1 membrane-encapsulation or 
by ciprofloxacin.
2.8. Eradication of Organ Infection in Mice Using 
J774A.1-Membrane-Encapsulated, Antimicrobial-Conjugated NPs
Macrophages with intracellular S. aureus can spread via the 
blood circulation to infect organs and increase the severity of 
disease.[16] Therefore, we also evaluated the antimicrobial effi-
cacy of mouse J774A.1 Me-ANPs in an established mouse organ 
infection model[13] after intravenous injection of infected mac-
rophages with in vivo internalized staphylococci to disseminate 
infection through the body. 2 h after intravenous infection of 
infected macrophages with intracellular S. aureus WHGFP, mice 
were injected with a single dose of PBS, ciprofloxacin, or J774A.1 
Me-ANPs. Mice were sacrificed at day four posttreatment after 
which various organs were removed, homogenized and plated 
(see Figure  8a). Mice demonstrated no visible adverse effects 
of Me-ANPs injection, while body weight of the mice showed 
little variation over the course of the infection period till sacri-
fice (Figure 8b) in line with the absence of in vitro cytotoxicity 
observed (Figure S12, Supporting Information). Staphylococcal 
CFUs retrieved per gram homogenized organ tissue are sum-
marized in Figure 8c for six organs. J774A.1 Me-ANPs demon-
strated significant killing by 2-3 log-units relative to PBS per 
gram organ tissue in all organs. In contrast, ciprofloxacin only 
showed significant killing of staphylococci disseminated to the 
kidneys.
3. Discussion
Nature-inspired, drug-loaded nanocarriers are emerging as an 
alternative for synthetic carriers, possessing a biocompatibility 
that is difficult to achieve with fully synthetic nanocarriers.[30] 
Here, we developed a novel amphiphilic, binary ANPs 
encapsulated in macrophage membranes. Binary antimicro-
bial-conjugates have been made before, like antibody-antibiotic 
conjugates to target specific pathogens,[13] but the current use 
of antimicrobial-conjugates that self-assemble through micelle 
formation into an antimicrobial NP and their stabilization 
by macrophage membranes is new. Macrophage-monocyte 
Me-ANPs retained a large variety of membrane proteins and 
critical Toll-like receptors on their surfaces from their parent 
cells (Figure  2e and Figure S7e, Supporting Information), 
including cell membrane TLRs (TLR2 and 4) as well as endo-
somal membrane TLRs (TLR 3 and 9). Membrane proteins 
were demonstrated to have been transferred to ANPs in an 
amount sufficient to exert their activities [37,52] and functions of 
transferred proteins were identified to coincide with those of 
proteins in macrophage-monocyte membranes.
However, apart from maintaining critical membrane com-
ponents upon isolation and coating, the transverse asymmetry 
of phospholipids in plasma membrane bilayers (“sidedness”) 
is functionally important. Particularly the orientation of phos-
phatidylserine as an “eat-me signal” or “picking side”, outward 
projection the N-termini of the TLRs and burial of their C-ter-
mini in the lumen are distinctive characteristics of membrane 
bilayers. Membrane sidedness is actively maintained in parent 
cells,[63] although the mechanisms by which this is achieved 
in living cells is not clear. According to Steck and Lange, the 
fundamental organizing feature of the membrane is the phos-
pholipid bilayer.[63] Polar head groups of phospholipids may be 
considered as a driving force for organizing membrane sided-
ness, creating a generally uncharged outer leaflet and strongly 
negatively charged inner leaflet.[64,65,66,67,68,69] It is likely that 
phospholipids in membrane fragments constitute a similar 
driving force in establishing a uniform sidedness in membrane 
Figure 7. In vivo antimicrobial efficacy of mouse J774A.1 membrane-encapsulated, antimicrobial-conjugated nanoparticles compared with PBS, cip-
rofloxacin and ANPs with and without membrane-encapsulation, assessed in a mouse, acute peritonitis model. a) Schematics of the mouse, acute 
peritonitis model used. b) The number of CFUs retrieved from 5 mL peritoneal fluid, extracted 2 d after intraperitoneal antimicrobial injection. Data 
are presented as means ± standard deviations for 5 mice per group. Asterisks above the data points indicate statistical significance at p < 0.05 (*), 
p < 0.01 (**), p < 0.001 (***), and p < 0.0001 (****), one-way ANOVA test.
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coatings as in cells. This suggestion is confirmed by the rela-
tively little negative zeta potentials of Me-ANPs (-25  mV; see 
Figure 2h) as compared with zeta potentials of membrane frag-
ments (-47 mV) that represent an average over both membrane 
sides. Apart from polarity as a driving force for maintaining 
sidedness in biomimetic membrane coatings, also nanopar-
ticle charge and diameter play a decisive role. Red blood cell 
membranes covered polymeric nanoparticles with the right side 
out, but only when the nanoparticles carried a negative charge 
and possessed a diameter between 65 and 340 nm.[70] The nega-
tive zeta potential (Figure 2h) and a diameter within the above 
range of the ANPs synthesized here (Figure  2b), suggest that 
our Me-ANPs may also have the right side of the membrane 
out, despite differences between red blood cell membranes and 
macrophage membranes.
Absence of cytotoxicity of Me-ANPs was confirmed in vitro 
based on a metabolic activity assay employing two non-phago-
cytic cell lines in addition to phagocytic J774A.1 and THP-1 
cell lines (Figure S12, Supporting Information). In vivo, when 
encapsulated with mouse J774A.1 macrophage membranes, 
there were no obvious adverse effects of Me-ANP after injection 
in mice. To avoid adverse immunological effects, human THP-1 
encapsulated antimicrobial-conjugated NPs were not evalu-
ated in mouse infection models. Engulfment of self-derived 
compounds occurs during untreated S. aureus infection as a 
result of tissue damage, and this has potential implications for 
Figure 8. In vivo antimicrobial efficacy of mouse J774A.1 macrophage membrane-encapsulated, antimicrobial-conjugated nanoparticles, assessed in a 
mouse, intravenous organ infection model. a) Schematics of the mouse, intravenous infection model used. Organ infection was induced by intravenous 
injection of 200 µL of a suspension of mouse macrophages with intracellular S. aureus WHGFP, followed after 2 h by intravenous injection of 200 µL PBS, 
or PBS with ciprofloxacin or Me-ANPs. b) Body weight of the mice as a function of time posttreatment by intravenous injection. Data are presented 
as means ± standard deviations over 5 mice per group. c) The number of CFUs retrieved from 1 g of homogenized organ tissue for different organs, 
excised 4 days after intravenous antimicrobial injection. Data are presented as means ± standard deviations over 5 mice per group. Asterisks above the 
data points indicate statistical significance at p < 0.05 (*), p < 0.01 (**), p < 0.001 (***) and p < 0.0001 (****), one-way ANOVA test.
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development of autoimmune responses. The novel approach as 
developed in the current study may differentially impact on how 
host antigens are processed and presented. Although human 
THP-1 cells yielded encapsulation of ANPs with similar proper-
ties as mouse J774A.1 encapsulated ones, this warrants further 
investigation, also in view of the rapidly expanding spectrum of 
bacterial pathogens co-driving autoimmune disease.
As an unexpected outcome, J774A.1 Me-ANPs were 
only engulfed by infected macrophages and not by sterile 
cells without internalized staphylococci. Enhanced engulf-
ment of modified, antimicrobial-loaded liposomes has been 
reported,[15,23,24] but the authors point out that the engulfment 
process itself remained poorly understood,[24] leaving many 
questions open. Providing a mechanism for selective engulf-
ment observed for macrophage Me-ANPs is accordingly even 
more difficult, but based on the differences measured for sterile 
and infected J774A.1 macrophages relevant for interaction with 
membrane-encapsulated, antimicrobial-conjugated nanopar-
ticles, we provide a model supported by a variety of data col-
lected and shown in Figure 2 (zeta potentials and abundance of 
Toll-like receptors), Figure 5 and Figure S11, Supporting Infor-
mation (lysozyme presence on cells after bacterial engulfment) 
that is schematically summarized in Figure 9.
Staphylococcal attachment to J774A.1 cells occurs through 
attractive Lifshitz-Van der Waals and specific ligand-receptor 
forces, despite electrostatic double-layer repulsion between the 
negatively-charged staphylococci and the J774A.1 cell surface 
(Figure 9, panel II). Thus, whereas sterile macrophages excrete 
lysozyme (Figure  9, panel I), data suggest that positively-
charged intracellular lysozyme molecules are recruited during 
engulfment (Figure 9, panel III) of a negatively-charged staph-
ylococcus and subsequent captured in the membrane upon 
closure of the phagocytic cup,[57] (Figure 9, panel IV). This pro-
cess leaves a positively-charged, lysozyme-rich membrane scar 
(Figure 9, panel V). The dimensions of these scars are expected 
to be comparable or slightly smaller than the bacterial diam-
eter of around 1 µm, but ≈10-fold larger than the Me-ANPs. The 
localized nature of these lysozyme-rich membrane scars follows 
from the overall negative zeta potential of the membrane 
from infected cells: positively charged lysozyme-rich scars will 
attract small, negatively charged Me-ANPs through electro-
static double-layer attraction (Figure S9, Supporting Informa-
tion),[71] yielding their engulfment (Figure 9, panel VI). Sterile 
cells only possess scattered lysozyme molecules (impossible 
to visualize using fluorescently labeled antibodies), embedded 
in a highly negative-charged membrane (Figure  9, panel I), 
thus overall repelling negatively charged Me-ANPs. Therewith 
membrane approach and engulfment of negatively charged Me-
ANPs toward sterile cells is inhibited by electrostatic-double 
layer repulsion. Selective internalization avoids unnecessary 
Figure 9. Proposed mechanism of selective engulfment of negatively-charged, macrophage membrane-encapsulated, antimicrobial-conjugated NPs 
into infected macrophages through lysozyme-rich scars created during staphylococcal engulfment. I) Sterile macrophages excrete lysozyme to kill 
extra-cellular planktonic bacteria. II) Positively charged lysozyme molecules are recruited to a partly engulfed, negatively charged staphylococcus. 
III–V) During recruitment, lysozyme is captured in the membrane upon closure of the phagocytic cup to leave a lysozyme-rich, positively charged 
membrane scar with dimensions comparable with the bacterial diameter, i.e., much larger than the NPs. VI) Positively-charged lysozyme scars attract 
negatively charged Me-ANPs to the membrane of an infected cell. Sterile cells only possess scattered lysozyme molecules, embedded in a highly 
negative-charged membrane repelling negatively charged Me-ANPs.
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consumption of Me-ANPs, and presents a potential advantage 
for clinical application, as healthy leukocytes in which no staph-
ylococci are hiding, will not be compromised. Experiments with 
macrophages and monocytes that are defective for lysozyme 
production, for instance as derived from lysM knockout 
mice, might confirm the mechanism proposed in Figure  9. 
Furthermore, it will be valuable to assess whether the selective 
internalization mechanism of Me-ANPs established here for 
macrophages-monocytes is also operational for low-phagocytic 
cells, types such as endothelium and other epithelia where 
S. aureus or other pathogens take up residence, sequestered 
away from immune cells. Other mechanistic work downstream 
of the novel lysozyme cupping mechanism we identify here, 
includes elucidation how and in which intracellular compart-
ments the antimicrobials are actually liberated. Intracellular 
compartments are unlikely to mingle, while Lacoma et  al.[12] 
have shown that S. aureus is present in acidic subcellular com-
partments expressing markers for late endosomes/lysosomes, 
like LAMP-1, Rab7 and RILP.
After engulfment by infected macrophages, the antimicro-
bial-conjugates kill infecting staphylococci more effectively than 
ciprofloxacin. In fact, in vivo ciprofloxacin yielded similarly low 
staphylococcal killing in an organ infection model (Figure  8c) 
as did PBS as a negative control. This is probably because 
ciprofloxacin, though able to enter mammalian cells and sub-
compartments such as phagosomes, is inactivated in the acidic 
environment of phagosomes.[72] This inactivation mechanism 
makes it likely that in our Me-ANPs, triclosan does the actual 
killing of pathogens in infected leukocytes, as triclosan is highly 
stable compared with ciprofloxacin. Its anaerobic degradation 
occurs not within 70 d, while aerobic degradation requires at 
least 18 d.[73] Importantly, the use of triclosan in soaps, deter-
gents, clothing, carpets, toys, school supplies and pacifiers is 
under heavy debate, but its use in healthcare is undisputed.[74]
4. Conclusion
In summary and perspective, we have demonstrated for the 
first time that binary, amphiphilic antimicrobial-conjugates 
self-assemble into antimicrobial NPs that can be stabilized for 
several weeks at pH 7.4 by encapsulation in mouse J774A.1 or 
human THP-1 membranes, as models for macrophages and 
monocytes, respectively. Acute peritonitis induced by staphy-
lococcal injection was more effectively eradicated by mouse 
macrophage membrane-encapsulated ANPs than by ANPs in 
absence of membrane-encapsulation, while both performed 
better than ciprofloxacin, the current clinical standard. In 
addition, mouse macrophage Me-ANPs showed up to 4 log-
units higher killing of staphylococci in various organs of mice, 
infected through hematogenous dissemination of macrophages 
with internalized staphylococci, than ciprofloxacin. Moreover, 
no adverse effects were observed upon intravenous injection 
of Me-ANPs and their circulation in the blood stream. Along 
similar lines, very recently, peritoneal liposomal vancomycin 
was demonstrated to reduce S. aureus kidney infection and 
mouse mortality, even when administered a day after infec-
tion.[11] Innovative lysosomal carriers are also being developed 
for tuberculosis therapy,[75] including liposomes for antibiotic 
delivery and immunization.[76] In addition, nanoparticles can 
be employed for tuberculosis therapy by promoting phago-
lysosome fusion (by metformin), phagosome acidification and 
maturation (imatinib), by inhibition of phagolysosome fusion 
(ManLAM), and by phagosome destabilization (ESX-1).[77]
For future large-scale clinical application, an off-the-shelf 
product can be envisioned based on a human monocyte cell 
line, preferably with very low or absent expression of major 
human leukocyte antigens to prevent alloimmunization.[78] 
Individualized treatment can be based on peripheral blood 
monocytes, but costs would be proportionally higher. Thus, 
leukocyte Me-ANPs can become a powerful means to eradi-
cate intracellular bacteria hiding in macrophages, for which 
there is currently no effective control strategy available in daily 
clinical practice.
5. Experimental Section
Synthesis of an Amphiphilic, Binary Antimicrobial Conjugate: A mixture 
of triclosan (2.89  g, 10  mmol, 1.0 equivalent), triethylamine (Et3N, 
1.11 g, 11 mmol, 1.1 equivalent) in anhydrous dichloromethane (CH2Cl2, 
100 mL) was cooled to -5 °C. Chloroacetyl chloride (1.13 g, 10 mmol, 1.0 
equivalent) in dry dichloromethane (20 mL) was added drop wise to this 
reaction mixture under stirring over a period of 1 h at -5 °C. Next, the 
reaction mixture was stirred overnight at room temperature, diluted with 
dichloromethane (100 mL), washed with 5% HCl (100 mL, 1×) and 5% 
sodium hydroxide solution (100 mL, 1×).
The organic layer was washed with saturated aqueous NaCl, dried 
over anhydrous magnesium sulfate, filtered and solvent was removed 
under reduced pressure. The crude product was purified on a silica gel 
column to yield the triclosan chloroacetyl derivative as a colorless oil 
(yield: 82%). 1H NMR (400  MHz, CDCl3) δ 7.55 (s, 1H), 7.37–7.23 (m, 
3H), 6.99 (d, J = 7.0 Hz, 1H), 6.89 (d, J = 7.0 Hz, 1H), 4.34 (s, 2H). 13C 
NMR (100  MHz, CDCl3) δ 165.02, 150.59, 146.73, 141.01, 130.61, 130.14, 
129.22, 128.38, 127.65, 126.40, 124.05, 120.99, 119.79, 40.35 (Figure S1, 
Supporting Information).
The triclosan chloroacetyl derivative (336  mg, 1.0  mmol), 
trimethylamine (0.416  mL, 3.0  mmol) and potassium iodide (249  mg, 
1.5 mmol) were added to a solution of ciprofloxacin (331 mg, 1.0 mmol) 
in dimethylformamide (5  mL) under argon atmosphere. The mixture 
was stirred at room temperature overnight and subsequently poured 
into water (50  mL). The resulting precipitate was filtered off, washed 
with water and recrystallized from methanol. Ciprofloxacin–triclosan 
conjugate (see Figure  10) was obtained as a yellow powder (560  mg, 
85%). 1H NMR (400  MHz, DMSO) δ 15.20 (s, 1H), 8.66 (s, 1H), 7.89 
(d, J = 13.1 Hz, 1H), 7.76 (d, J = 2.5 Hz, 1H), 7.55 (t, J = 7.1 Hz, 2H), 7.40 
(dd, J = 8.8, 2.5 Hz, 2H), 7.16 (d, J = 8.8 Hz, 1H), 6.96 (d, J = 8.9 Hz, 1H), 
3.81 (s, 1H), 3.55 (s, 2H), 2.73 (s, 4H), 1.31 (d, J  = 6.7  Hz, 2H), 1.17 
(s, 2H), 13C NMR (100  MHz, DMSO) δ 176.80, 168.18, 166.38, 151.23, 
148.38, 146.51, 145.56, 141.87, 139.59, 130.56, 129.26, 128.94, 128.87, 127.97, 
125.11, 124.93, 121.92, 120.67, 111.51, 111.28, 106.81, 58.15, 51.78, 49.82, 
49.77, 36.29, 8.05. MALDI-TOF MS (m/Z, [M+H]+, calculated: 660.0866, 
662.0836, 661.0889, 663.0870, 664.0807; found: 660.0869, 662.0841, 
661.0933, 663.0888, 664.0795) (Figure S2, Supporting Information).
The critical micelle concentration (CMC) of the antimicrobial 
conjugates was measured using pyrene as a fluorescence probe. To this 
end, pyrene (0.6 × 10−3 m) was dissolved in acetone and 10 µL aliquots 
were added into tubes allowing evaporation of acetone and mixed 
with conjugate solution (450 µL) with different concentrations under 
overnight shaking in dark. Fluorescence emission spectra between 350 
and 500  nm were recorded on a fluorescence spectrometer (Hitachi 
F-4600, Tokyo, Japan) at an excitation wavelength of 334 nm. The change 
in linearity between the fluorescence intensity ratios at 373  nm and 
384 nm (I373/I384) and antimicrobial conjugate concentration was taken 
as the conjugate CMC.[79]
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Isolation of Mouse J774A.1 and Human THP-1 Cell Membranes: 
Mouse J774A.1 (ATCC TIB-67) and human THP-1 (ATCC TIB-202) cells 
were purchased from American Type Culture Collection to model 
mouse macrophages and human monocytes, respectively. Leukocytes 
were cultured in Dulbecco’s modified Eagle’s medium (high glucose, 
Gibco, Thermo Fisher Scientific, MA, USA) supplemented with 10% 
fetal bovine serum (FBS, Gibco) and 0.1% L-ascorbic acid 2-phosphate 
sesquimagnesium salt (AA2P, Sigma) at 37 °C in a humidified 5% CO2 
incubator.
In order to isolate cell membranes, cells were harvested using a cell 
scraper at 80–90% confluency and resuspended at a concentration of 
2.5 × 107 cell mL−1 in ice-cold tris-magnesium buffer (TM buffer, pH 7.4, 
0.01 m tris and 0.001 m MgCl2) and 1 EDTA-free mini protease inhibitor 
tablet (Pierce, ThermoFisher Scientific) per 10 mL of suspension. Cells 
were denucleated using a sonicator (Vibra cell model 375, Sonics 
and Material, Inc., Danbury, CT) for 4 × 10 s, while cooling in an ice/
water bath. The homogenate was mixed with 1 m sucrose to a final 
concentration of 0.25 m sucrose, and centrifuged at 2000 g  and 4 °C 
for 10  min. The supernatant was collected and further centrifuged at 
20 000 g and 4 °C for 30 min in order to collect leukocyte membranes. 
Membranes were washed with ice-cold TM-buffer with 0.25 m of sucrose 
and collected by centrifugation at 20 000 g  and 4 °C for 30  min and 
stored at -20 °C for further use.
Antimicrobial-Conjugated Nanoparticles (ANPs) Preparation and 
Macrophage-Monocyte Membrane-Encapsulation: For the preparation 
of ANPs, 200  µL of binary antimicrobial-conjugate stock solution in 
dimethylsulfoxide (10 mg mL−1) was added dropwise to 5 mL ultrapure 
water under magnetic stirring (2500  rpm) to form an ANP suspension 
through self-assembly, occurring by virtue of their amphiphilic character. 
After further stirring for 30 min, the ANPs suspension was centrifuged 
at 20,000 g (centrifuge 5417R, Eppendorf, Germany) and 4 °C for 30 min 
to collect the ANPs. Then, ANPs were rinsed once with ultrapure 
water (5 mL) to remove the residual organic solvent. Finally, the ANPs 
were resuspended in 2  mL ultrapure water to a final concentration of 
1 mg mL−1 and stored at 4 °C for further use.
For macrophage-monocyte membrane-encapsulation, ANP 
suspensions (2  mL) were mixed with membranes isolated from a 
total of 5 × 106 leukocytes. The resulting mixture was homogenized 
using a sonicator for 4 × 10 s while cooling in an ice/water bath. The 
encapsulated ANPs were centrifuged at 20 000 g and 4 °C for 30 min and 
washed once with cold ultrapure water. Finally, membrane-encapsulated 
(Me) ANPs were collected and resuspended in 2 mL ultrapure water to a 
final concentration of 1 mg mL−1 and stored at 4 °C for further use.
Nanoparticle Characterization, Stability and Antimicrobial-Conjugate 
Release: Transmission electron microscopy (TEM) was performed to 
demonstrate the presence of membrane-encapsulation and ANPs 
stability, using a Glacios Cryo-TEM (Thermo Scientific, Massachusetts, 
United States) at an acceleration voltage of 200 kV. TEM samples were 
prepared by applying a droplet of a ANPs or Me-ANPs suspension onto 
a carbon coated copper grid and drying it at room temperature.
Hydrodynamic diameters of the ANPs with or without membrane-
encapsulation were measured at 25 °C using a Zetasizer Nano-ZS 
(Malvern Instruments, Worcestershire, UK) in 10  × 10−3 m potassium 
phosphate buffer as a function of storage time in buffer. Similarly, zeta 
potentials and polydispersity indices (PDI) of the ANPs were measured 
using the same instrument. Both types of measurements were done 
at an ANP concentration of 0.1  mg mL−1. Drug-loading in ANPs was 
measured using UV–vis absorption spectroscopy (Shimadzu, Japan). 
First absorption spectra were taken at different antimicrobial-conjugate 
concentrations (Figure S6a, Supporting Information) and a calibration 
curve (Figure S6b, Supporting Information) was prepared using the 
unique absorption peak of the antimicrobial-conjugate at 281  nm 
for quantitation (Figure S6c, Supporting Information). The UV–vis 
calibration curve was also applied to determine the release of conjugates 
from the ANPs in absence and presence of membrane-encapsulation. 
To this end, 2 mL ANP suspension (1.0 mg mL−1) was transferred into 
a dialysis bag (molecular weight cut off: 12−14  kDa) and subsequently 
immersed in 20 mL PBS (pH 7.4 and pH 5.0) at 37 °C. Aliquots (1 mL) 
of the dialysis solution were collected every 30 min up to 72 h, and the 
absorbance of the solutions at 281 nm was recorded. The volume of the 
stock dialysis solution was kept constant by adding 1 mL of fresh buffer, 
after each aliquot was taken.
In order to identify the proteins on the macrophage-monocyte 
membranes isolated and on Me-ANPs, proteomic analyses were 
employed. Proteins were precipitated from membranes or Me-ANPs 
using the ProteoExtract Kit (Merck, Darmstadt, Germany), as described 
in the user guide. Precipitated proteins were solubilized in 25 × 10−3 m 
ammonium bicarbonate containing 0.1% RapiGest (Waters, Eschborn, 
Germany) at 80 °C for 15 min. Proteins were reduced by adding 5 × 10−3 m 
DTT (45  min, 56 °C), and free cysteines alkylated with iodoacetamide 
(Sigma, Taufkirchen, Germany) (15  × 10−3 m, 25 °C, 1 h in the dark). 
0.2 µg porcine sequencing grade trypsin (Promega, Mannheim, 
Germany) was added and samples incubated overnight at 37 °C. After 
incubation, RapiGest was hydrolyzed by adding 10 × 10−3 m HCl (37 °C, 
10  min). The resulting precipitate was removed by centrifugation 
(13 000  g, 15  min, 4 °C), and the supernatant was transferred into an 
autosampler vial for peptide analysis using liquid chromatogrpahy-mass 
spectroscopy (LC-MS).[52] LC-MS data were employed in UniProt/GO[51] 
to determine characteristic functions of the membrane proteins.
Staphylococcal Culturing and Harvesting: Two multidrug-resistant 
staphylococcal strains[45] were employed in this study: green-fluorescent 
S. aureus WHGFP and commercially available bioluminescent S. aureus 
Xen36 (PerkinElmer Inc., Waltham, MA, USA). Both strains were 
cultured at 37 °C in ambient air. S. aureus WHGFP was cultured on 
Tryptone soy broth (TSB, OXOID, Basingstoke, UK) agar plates with 
10  µg m−1 tetracycline, while S. aureus Xen36 was cultured on agar 
plates with 200 µg mL−1 kanamycin. One colony was inoculated in 10 mL 
TSB medium with 10 µg mL−1 tetracycline for S. aureus WHGFP and for 
S. aureus Xen36 TSB and incubated for 24 h at 37 °C, this preculture was 
inoculated (1:20) into 200 mL main culture and grown for 16 h. Bacterial 
cultures were harvested by centrifugation for 5  min at 5000g,  washed 
twice in PBS and sonicated for three times 10 s (Vibra cell model 375, 
Sonics and Material Inc., Danbury, CT), while cooling in an ice/water 
bath to break possible aggregates. Finally, suspensions were diluted 
in PBS to concentrations required in the respective experiments, as 
determined in a Bürker-Türk counting chamber.
Engulfment of Macrophage-Monocyte Membrane-Encapsulated, 
Antimicrobial-Conjugated Nanoparticles into J774A.1 Macrophages In 
Figure 10. Conjugation of hydrophobic triclosan and hydrophilic ciprofloxacin.
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Vitro: For Engulfment Studies: Nile red-loaded, Me-ANPs were prepared, 
essentially as described above for the preparation of ANPs. However, 
during ANP preparation, Nile red in dimethylformamide (40 µL, 1 mg mL−1) 
was added. For comparison, Nile red-loaded PC-liposomes were included, 
prepared by mixing a Nile red stock solution in dimethylformamide 
(40 µL, 1  mg mL−1) with phosphocholine-based phospholipids 
(DPPC, DSPC and DOPC) and cholesterol (Avanti Polar Lipids) in a 
chloroform:methanol mixture (200 µL, 3:1 v/v, 5  mg mL−1) to a total 
volume of 2 mL in PBS.
To study engulfment of macrophage-monocyte Me-ANPs and 
PC-liposomes in sterile and bacterially infected J774A.1 macrophages, 
infected cells were prepared by in vitro internalization of staphylococci. 
Briefly, J774A.1 cells were seeded at a density of 4 × 105 cells mL−1 in 
six-well-plates and grown for 12 h at 37 °C in a 5% CO2 incubator. 
Subsequently, the cell-culture was infected with S. aureus WHGFP at 
a ratio of 20 bacteria per cell and supplemented with 100 µg mL−1 of 
gentamicin, as a widely used tool to prevent growth of extracellular 
staphylococci. After coculturing for 24 h at 37 °C in a 5% CO2 incubator, 
the wells were gently emptied and washed once with 1  mL PBS 
to remove non-internalized staphylococci. After removal of growth 
medium, 2 mL freshly prepared Nile red-loaded Me-ANPs or PC-liposomes 
(0.1  mg mL−1 in PBS, see above) were added to each well, followed by 
culturing at 37 °C for 2 h. Subsequently, the cell culture was rinsed by PBS 
(1  mL per well), fixed with 3.7% paraformaldehyde for 15  min at room 
temperature and permeabilized with 0.1% Triton X-100 (1  mL well−1) in 
PBS. Nuclei were stained with 4’,6-diamidino-2-phenylindole (DAPI) 
in PBS (4 µg mL−1) for 1 h at room temperature. J774A.1 cells with 
internalized red-fluorescent Me-ANPs or PC-liposomes were observed 
using a CLSM.
For CLSM, a TCS SP2 (Leica, Wetzlar, Germany) was used, 
equipped with an argon ion laser at 488 nm to excite green-fluorescent 
staphylococcal protein and a 543 nm green neon laser to excite Nile red. 
A solid-state 405 nm laser was used for excitation of DAPI. Fluorescence 
signals were detected at 430–500  nm (blue, cellular nuclei), 500–
535  nm (green, staphylococci) and 583–688  nm (red, due to Nile red 
in Me-ANPs). All data were acquired and analyzed using Leica software, 
version 2.0 and Image J software.
Lysozyme Distribution on Sterile and Infected Macrophage-
Monocyte Membranes: Lysozyme distribution on sterile and infected 
macrophages-monocytes was compared using immunofluorescence 
staining immediately and 12 h after infection (only for J774A.1 cells). 
For immediate analysis using CLSM, sterile cells and cells infected 
with green-fluorescent S. aureus WHGFP (see above), cells were fixed 
in 4% paraformaldehyde for 15  min at room temperature, washed 
three times with PBS and exposed to 5% fetal bovine serum for 1 h, 
followed by staining with lysozyme primary antibodies (rabbit anti-
lysozyme antibody, Abcam, Cat#EPR2994(2)) 16 h at 4 °C, according 
to the manufacturer’s instructions. Anti-lysozyme antibodies were 
applied for labeling in absence of Triton X-100 in order to avoid entry 
of anti-lysozyme antibodies into the cell and labeling of lysozyme inside 
the cell.[59] Subsequently, fluorescently labeled secondary antibodies 
(Donkey anti-Rabbit, Invitrogen, Cat#A32754) were added for 1.5 h. 
All antibodies were applied at concentration 5 µg mL−1 in PBS. Finally, 
the nuclei of macrophages were stained with blue-fluorescent DAPI. 
Lysozyme distribution was observed using CLSM, as described above. 
For analysis of the time-dependence of lysozyme presence, infected 
macrophages were analyzed by flow cytometry. Sterile cells and 
cells infected with green-fluorescent S. aureus WHGFP, were washed 
three times with PBS and followed by staining with lysozyme primary 
antibodies 0.5 h at room temperature, according to the manufacturer’s 
instructions and washed three times. Subsequently, fluorescently 
labeled secondary antibodies were added for 0.5 h at room temperature, 
after washing three times, FACS was used to quantify red-fluorescent 
lysozyme presence.
Antimicrobial Efficacy of Macrophage-Monocyte Membrane-
Encapsulated, Antimicrobial-Conjugated Nanoparticles In Vitro: 
To determine the MIC of macrophage-monocyte Me-ANPs and 
their composing antimicrobials, 100 µL of each in PBS (triclosan, 
ciprofloxacin, 1:1 mixture of triclosan and ciprofloxacin, Me-ANPs, all 
at equivalent antimicrobial concentrations between 0 and 80 µg mL−1) 
were applied to 100 µL suspension of S. aureus WHGFP or S. aureus 
Xen36 in PBS (2 × 106 bacteria mL−1). MIC values were taken as the 
lowest concentration at which visible bacterial growth was absent. 
Subsequently, the MBC values were determined by plating aliquots 
of suspensions with concentrations yielding no visible growth of 
bacteria on TSB agar plates. The lowest concentration at which no 
colony forming units appeared after 24 h growth at 37 °C was taken 
as the MBC.
In Vitro Killing of Staphylococci Hiding in Macrophages by Mouse J774A.1 
Membrane-Encapsulated, Antimicrobial-Conjugated Nanoparticles: In order 
to compare the intracellular killing efficacy by mouse J774A.1 Me-ANPs 
with ciprofloxacin and PBS as a control, infected J774A.1 macrophages 
were exposed for 24 h to Me-ANPs, ciprofloxacin or PBS, similarly as 
described under “Engulfment of membrane-encapsulated, antimicrobial 
nanoparticles into leukocytes in vitro” (see above). After 24 h, cells 
were lysed in PBS supplemented with 0.1% bovine serum albumin and 
0.1% Triton-X. Lysate was homogenized by sonication on a JY98-IIIDN 
(Scientz, Ningbo, China), and serial dilutions of the lysate were made in 
PBS containing 0.05% Tween-20. The number of staphylococci surviving 
inside macrophages was determined by plating on tryptic soy agar with 
5% defibrinated sheep blood.
Mouse Acute Peritonitis Model for Evaluating the Killing of 
Staphylococci by Mouse J774A.1 Membrane-Encapsulated, Antimicrobial-
Conjugated Nanoparticles: Eight week old female mice, ICR (CD-1) 
(35 g to 40 g each) were obtained from Vital River Laboratory Animal 
Technology Co. (Beijing, China). All animals were housed in the on-site 
animal facility of Nankai University and experimental procedures 
were approved by the Institutional Animal Care and Use Committee 
of Nankai University, Tianjin, China. Each mouse was injected with a 
dose of 2 × 108 S. aureus WHGFP directly into the peritoneal cavity. At 
day 1 after bacterial injection, infected animals were randomly assigned 
into four groups of five animals each, receiving intraperitoneal 
injection of i) 200  µL PBS (negative control), ii) 200  µL ciprofloxacin 
in PBS (1 mg mL−1), iii) 200 µL ANPs without membrane-encapsulation 
in PBS (1  mg mL−1) and iv) 200  µL Me-ANPs with membrane-
encapsulation in PBS (1 mg mL−1). Treatment was initiated 1 day post-
injection and continued for 2 consecutive days. All mice were killed 
on day 3 after injection. Peritoneal macrophages were harvested by 
washing the peritoneal cavity with 5 mL cold PBS. Macrophages were 
lysed by homogenization on a JY98-IIIDN sonicator (Scientz, Ningbo, 
China), and serial dilutions of the lysate were made in PBS containing 
0.05% Tween-20. The number of surviving peritoneal bacteria was 
determined by plating on tryptic soy agar plates supplemented with 
5% defibrinated sheep blood.
Mouse Organ Infection Model for Evaluating the Killing of Staphylococci 
by Mouse J774A.1 Membrane-Encapsulated, Antimicrobial-Conjugated 
Nanoparticles: Peritoneal macrophages with infecting staphylococci from 
different pairs of donor mice were pooled, and injected intravenously 
into the tail vein of receptor mice in order to allow hematogenous 
spreading and dissemination of staphylococci to cause organ infection. 
Infected mice were randomly assigned into three groups of five animals, 
each receiving intravenous injection of i) 200  µL PBS, ii) 200  µL 
ciprofloxacin in PBS (1  mg mL−1), iii) 200  µL mouse J774A.1 Me-ANPs 
suspended in PBS (1 mg mL−1). All animals were sacrificed on day 4 after 
infection. Blood, heart, liver, spleen, lungs, and kidneys were harvested 
in 5 mL of sterilized PBS. Organs were homogenized using a JY98-IIIDN 
sonicator and the number of surviving bacteria per gram homogenized 
organ tissue was determined by plating serial dilutions of the tissue 
homogenates in PBS with 0.05% Tween on tryptic soy agar with 5% 
defibrinated sheep blood.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
Adv. Funct. Mater. 2020, 2004942
www.afm-journal.dewww.advancedsciencenews.com
2004942 (15 of 16) © 2020 The Authors. Published by Wiley-VCH GmbH
Acknowledgements
Y.L. and Y.L. contributed equally to this work. This work was financially 
supported by the National Natural Science Foundation of China 
(21620102005, 51933006), and the National Institutes of Health (VR, 
R01 AI134770), the State Key Laboratory of Medicinal Chemical biology 
(Grant No. 2019016), Nankai University.
Conflict of Interest
H.J.B. is also director-owner of a consulting company SASA BV. The 
authors declare no potential conflicts of interest with respect to 
authorship and/or publication of this article. Opinions and assertions 
contained herein are those of the authors and are not construed as 
necessarily representing views of the funding organizations or their 
employer(s).
Keywords
bacterial infections, cell membrane encapsulation, ciprofloxacin, Toll-like 
receptors, triclosan
Received: June 10, 2020
Revised: August 20, 2020
Published online: 
[1] World Health Organization, Antimicrobial Resistance: Global Report 
on Surveillance, World Health Organization, Geneva, Switzerland 
2014.
[2] S. B.  Halstead, S.  Mahalingam, M. A.  Marovich, S.  Ubol, 
D. M. Mosser, Lancet Infect. Dis. 2010, 10, 712.
[3] R. Boudjemaa, K. Steenkeste, C.  Jacqueline, R. Briandet, J. Caillon, 
D.  Boutoille, V.  Le Mabecque, P.  Tattevin, M.-P.  Fontaine-Aupart, 
M. Revest, J. Antimicrob. Chemother. 2018, 73, 2418.
[4] A.  Mantovani, M. A.  Cassatella, C.  Costantini, S.  Jaillon, Nat. Rev. 
Immunol. 2011, 11, 519.
[5] L. A. Knodler, J. Celli, B. B. Finlay, Nat. Rev. Mol. Cell Biol. 2001, 2, 
578.
[6] G.  Mitchell, C.  Chen, D. A.  Portnoy, Microbiol. Spectr. 2016, 4, 
MCHD-0012-2015.
[7] R. K. Ernst, T. Guina, S. I. Miller, J. Infect. Dis. 1999, 179, S326.
[8] B. G. J.  Surewaard, J. F. Deniset, F. J. Zemp, M. Amrein, M. Otto, 
J.  Conly, A.  Omri, R. M.  Yates, P.  Kubes, J. Exp. Med. 2016, 213, 
1141.
[9] R. S. Flannagan, B. Heit, D. E. Heinrichs, Cell. Microbiol. 2016, 18, 
514.
[10] R. S. Flannagan, R. C. Kuiack, M. J. McGavin, D. E. Heinrichs, MBio 
2018, 9, e01143.
[11] S. K.  Jorch, B. G. J.  Surewaard, M.  Hossain, M.  Peiseler, 
C. Deppermann, J. Deng, A. Bogoslowski, F. van der Wal, A. Omri, 
M. J. Hickey, P. Kubes, J. Clin. Invest. 2019, 129, 4643.
[12] A.  Lacoma, V.  Cano, D.  Moranta, V.  Regueiro, D.  Domínguez-
Villanueva, M.  Laabei, M.  González-Nicolau, V.  Ausina, C.  Prat, 
J. A. Bengoechea, Virulence 2017, 8, 1761.
[13] E. E.  McClure, A. S. O.  Chávez, D. K.  Shaw, J. A.  Carlyon, 
R. R.  Ganta, S. M.  Noh, D. O.  Wood, P. M.  Bavoil, K. A.  Brayton, 
J. J. Martinez, Nat. Rev. Microbiol. 2017, 15, 544.
[14] H. D.  Gresham, J. H.  Lowrance, T. E.  Caver, B. S.  Wilson, 
A. L. Cheung, F. P. Lindberg, J. Immunol. 2000, 164, 3713.
[15] S. Menina, H. I. Labouta, R. Geyer, T. Krause, S. Gordon, P. Dersch, 
C.-M. Lehr, RSC Adv. 2016, 6, 41622.
[16] S. M. Lehar, T. Pillow, M. Xu, L. Staben, K. K. Kajihara, R. Vandlen, 
L.  DePalatis, H.  Raab, W. L.  Hazenbos, J.  Hiroshi Morisaki, 
J. Kim, S. Park, M. Darwish, B. C. Lee, H. Hernandez, K. M. Loyet, 
P. Lupardus, R. Fong, D. Yan, C. Chalouni, E. Luis, Y. Khalfin, E. Plise, 
J. Cheong, J. P. Lyssikatos, M. Strandh, K. Koefoed, P. S. Andersen, 
J. A. Flygare, M. Wah Tan, E. J. Brown, S. Mariathasan, Nature 2015, 
527, 323.
[17] N.  Sémiramoth, C.  Di Meo, F.  Zouhiri, F.  Saïd-Hassane, 
S. Valetti, R. Gorges, V. Nicolas, J. H. Poupaert, S. Chollet-Martin, 
D. Desmaële, ACS Nano 2012, 6, 3820.
[18] A. M.  Walenkamp, W. S.  Chaka, A. F.  Verheul, V. V.  Vaishnav, 
R.  Cherniak, F. E.  Coenjaerts, I. M.  Hoepelman, FEMS Immunol. 
Med. Microbiol. 1999, 26, 309.
[19] J. J. Boelens, J. Dankert, J. L. Murk, J. J. Weening, T. Van Der Poll, 
K. P. Dingemans, L. Koole, J. D. Laman, S. A. J. Zaat, J. Infect. Dis. 
2000, 181, 1337.
[20] J. M. A.  Blair, M. A.  Webber, A. J.  Baylay, D. O.  Ogbolu, 
L. J. V. Piddock, Nat. Rev. Microbiol. 2015, 13, 42.
[21] E. D. Brown, G. D. Wright, Nature 2016, 529, 336.
[22] Y. Liu, H. C. van der Mei, B. Zhao, Y. Zhai, T. Cheng, Y. Li, Z. Zhang, 
H. J. Busscher, Y. Ren, L. Shi, Adv. Funct. Mater. 2017, 27, 1701974.
[23] Y. K.  Oh, D. E.  Nix, R. M.  Straubinger, Antimicrob. Agents Chem-
other. 1995, 39, 2104.
[24] S.  Menina, J.  Eisenbeis, M. A. M.  Kamal, M.  Koch, M.  Bischoff, 
S.  Gordon, B.  Loretz, C.  Lehr, Adv. Healthcare Mater. 2019, 8, 
1900564.
[25] D. Wang, H. C. van der Mei, Y. Ren, L. S. Henk, J. Busscher, Front. 
Chem. 2020, 7, 872.
[26] C.  Li, X.  Zhang, X.  Huang, X.  Wang, G.  Liao, Z.  Chen, Int. J. 
Nanomed.Nanomedicine 2013, 8, 1285.
[27] J.-F. Marier, J.  Lavigne, M. P. Ducharme, Antimicrob. Agents Chem-
other. 2002, 46, 3776.
[28] A.  Parodi, N.  Quattrocchi, A. L.  van de  Ven, C.  Chiappini, 
M.  Evangelopoulos, J. O.  Martinez, B. S.  Brown, S. Z.  Khaled, 
I. K.  Yazdi, M. V.  Enzo, L.  Isenhart, M.  Ferrari, E.  Tasciotti, Nat. 
Nanotechnol. 2013, 8, 61.
[29] Y.  Liu, L.  Shi, L.  Su, H. C.  van der  Mei, P. C.  Jutte, Y.  Ren, 
H. J. Busscher, Chem. Soc. Rev. 2019, 48, 428.
[30] Z. Mao, R. Cartier, A. Hohl, M. Farinacci, A. Dorhoi, T.-L. Nguyen, 
P. Mulvaney, J. Ralston, S. H. E. Kaufmann, H. Mohwald, D. Wang, 
Nano Lett 2011, 11, 2152.
[31] R. Li, Y. He, S. Zhang, J. Qin, J. Wang, Acta Pharm. Sin. B 2018, 8, 
14.
[32] R. H. Fang, Y. Jiang, J. C. Fang, L. Zhang, Biomaterials 2017, 128, 69.
[33] J. A.  Copp, R. H.  Fang, B. T.  Luk, C.-M. J.  Hu, W.  Gao, K.  Zhang, 
L. Zhang, Proc. Natl. Acad. Sci. USA 2014, 111, 13481.
[34] Z.  Pang, C. M. J.  Hu, R. H.  Fang, B. T.  Luk, W.  Gao, F.  Wang, 
E.  Chuluun, P.  Angsantikul, S.  Thamphiwatana, W.  Lu, X.  Jiang, 
L. Zhang, ACS Nano 2015, 9, 6450.
[35] S.  Thamphiwatana, P.  Angsantikul, T.  Escajadillo, Q.  Zhang, 
J. Olson, B. T. Luk, S. Zhang, R. H. Fang, W. Gao, V. Nizet, L. Zhang, 
Proc. Natl. Acad. Sci. USA 2017, 114, 11488.
[36] Q.  Zhang, D.  Dehaini, Y.  Zhang, J.  Zhou, X.  Chen, L.  Zhang, 
R. H. Fang, W. Gao, L. Zhang, Nat. Nanotechnol. 2018, 13, 1182.
[37] C. Wang, Y. Wang, L. Zhang, R. J. Miron, J.  Liang, M. Shi, W. Mo, 
S. Zheng, Y. Zhao, Y. Zhang, Adv. Mater. 2018, 30, 1804023.
[38] M. P.  Lopez-Jornet, G. Garcia-Teresa, M. Vinas, T. Vinusa, J. Dent. 
2011, 39, 757.
[39] D. J. Leaper, C. E. Edmiston, C. E. Holy, Br. J. Surg. 2017, 104, e134.
[40] M.  Renko, N.  Paalanne, T.  Tapiainen, M.  Hinkkainen, T.  Pokka, 
S.  Kinnula, J. J.  Sinikumpu, M.  Uhari, W.  Serlo, Lancet Infect. Dis. 
2017, 17, 50.
[41] F. D. Lowy, N. Engl. J. Med. 1998, 339, 520.
[42] Q. Cai, Y. Fei, H.-W. An, X.-X. Zhao, Y. Ma, Y. Cong, L. Hu, L.-L. Li, 
H. Wang, ACS Appl. Mater. Interfaces 2018, 10, 9197.
Adv. Funct. Mater. 2020, 2004942
www.afm-journal.dewww.advancedsciencenews.com
2004942 (16 of 16) © 2020 The Authors. Published by Wiley-VCH GmbH
[43] S.  Yang, X.  Han, Y.  Yang, H.  Qiao, Z.  Yu, Y.  Liu, J.  Wang, T.  Tang, 
ACS Appl. Mater. Interfaces 2018, 10, 14299.
[44] J. M. Domagala, J. Antimicrob. Chemother. 1994, 33, 685.
[45] Y.  Liu, Y.  Ren, Y.  Li, L.  Su, Y.  Zhang, F.  Huang, J.  Liu, J.  Liu, 
T. G. van Kooten, Y. An, L. Shi, H. C. van der Mei, H. J. Busscher, 
Acta Biomater 2018, 79, 331.
[46] Y. Liu, H. J. Busscher, B. Zhao, Y. Li, Z. Zhang, H. C. van der Mei, 
Y. Ren, L. Shi, ACS Nano 2016, 10, 4779.
[47] C.  Corbo, R.  Molinaro, F.  Taraballi, N. E.  Toledano Furman, 
K. A. Hartman, M. B. Sherman, E. De Rosa, D. K. Kirui, F. Salvatore, 
E. Tasciotti, ACS Nano 2017, 11, 3262.
[48] R. Medzhitov, Nature 2007, 449, 819.
[49] S. Akira, S. Uematsu, O. Takeuchi, Cell 2006, 124, 783.
[50] R. Medzhitov, Nat. Rev. Immunol. 2001, 1, 135.
[51] A. Bateman, Nucleic Acids Res 2019, 47, D506.
[52] R.  Molinaro, C.  Corbo, J. O.  Martinez, F.  Taraballi, 
M.  Evangelopoulos, S.  Minardi, I. K.  Yazdi, P.  Zhao, E.  De Rosa, 
M. B.  Sherman, A.  De Vita, N. E.  Toledano Furman, X.  Wang, 
A. Parodi, E. Tasciotti, Nat. Mater. 2016, 15, 1037.
[53] A.-M. Pauwels, M. Trost, R. Beyaert, E. Hoffmann, Trends Immunol 
2017, 38, 407.
[54] M. O. Eze, L. Yuan, R. M. Crawford, C. M. Paranavitana, T. L. Hadfield, 
A. K. Bhattacharjee, R. L. Warren, D. L. Hoover, Infect. Immun. 2000, 
68, 257.
[55] Q. Cai, Y. Fei, L. Hu, Z. Huang, L.-L. Li, H. Wang, Nano Lett. 2018, 
18, 6229.
[56] E. Chibowski, A. Szcześ, Adsorption 2016, 22, 755.
[57] N. Jain, J. Moeller, V. Vogel, Annu. Rev. Biomed. Eng. 2019, 21, 267.
[58] S. A. Ragland, A. K. Criss, PLOS Pathog 2017, 13, e1006512.
[59] Immunocytochemistry and immunofluorescence protocol, https://
www.abcam.com/protocols/immunocytochemistry-immunofluores-
cence-protocol, (accessed: July  2020).
[60] C.  Vingsbo Lundberg, T.  Vaara, N.  Frimodt-Moller, M.  Vaara, 
J. Antimicrob. Chemother. 2010, 65, 981.
[61] A.  Nandi, S.  Dey, J.  Biswas, P.  Jaiswal, S.  Naaz, T.  Yasmin, 
B. Bishayi, Inflammation 2015, 38, 224.
[62] B. C.  Kahl, K.  Becker, B.  Löffler, Clin. Microbiol. Rev. 2016, 
29, 401.
[63] T. L. Steck, Y. Lange, Traffic 2018, 19, 750.
[64] J. A. F. Op den Kamp, Annu. Rev. Biochem. 1979, 48, 47.
[65] A. Zachowski, Biochem. J. 1993, 294, 1.
[66] J. D.  Nickels, J. C.  Smith, X.  Cheng, Chem. Phys. Lipids 2015, 
192, 87.
[67] O. Engberg, V. Hautala, T. Yasuda, H. Dehio, M. Murata, J. P. Slotte, 
T. K. M. Nyholm, Biophys. J. 2016, 111, 546.
[68] M.  Murate, M.  Abe, K.  Kasahara, K.  Iwabuchi, M.  Umeda, 
T. Kobayashi, J. Cell Sci. 2015, 128, 1627.
[69] M. Murate, T. Kobayashi, Chem. Phys. Lipids 2016, 194, 58.
[70] B. T.  Luk, C. M.  Jack Hu, R. H.  Fang, D.  Dehaini, C.  Carpenter, 
W. Gao, L. Zhang, Nanoscale 2014, 6, 2730.
[71] C. J. Van Oss, Annu. Rev. Microbiol. 1978, 32, 19.
[72] B. Bishayi, S. Dey, J. Inflamm. Res. 2015, 8, 29.
[73] G.-G. Ying, X.-Y. Yu, R. Kookana, Environ. Pollut. 2007, 150, 300.
[74] R. U. Halden, Environ. Sci. Technol. 2014, 48, 3603.
[75] P. Minakshi, M. Ghosh, B. Brar, R. Kumar, U. P. Lambe, K. Ranjan, 
J. Manoj, G. Prasad, Curr. Pharm. Des. 2019, 25, 1554.
[76] G. R. Diogo, P. Hart, A. Copland, M.-Y. Kim, A. C. Tran, N. Poerio, 
M. Singh, M. J. Paul, M. Fraziano, R. Reljic, Front. Immunol. 2019, 
10, 1349.
[77] R. S. Wallis, R. Hafner, Nat. Rev. Immunol. 2015, 15, 255.
[78] S. Depil, P. Duchateau, S. A. Grupp, G. Mufti, L. Poirot, Nat. Rev. 
Drug Discovery 2020, 19, 185.
[79] J. Aguiar, P. Carpena, J. A. Molina-BolÍvar, C. Carnero Ruiz, J. Colloid 
Interface Sci. 2003, 258, 116.
Adv. Funct. Mater. 2020, 2004942
